MapQuant Dx Genomic Grade Test Identifies Breast Cancer Patients
Ipsogen SA is entering the breast cancer diagnostic market with the European launch of MapQuant Dx Genomic Grade. MapQuant Dx Genomic Grade is the very first molecular diagnostic test to accurately measure tumor grade, a consensus indicator of tumor proliferation, risk of metastasis and response to chemotherapy.
Histological tumor grading is considered a decision factor in most national and international guidelines to breast cancer treatment. While it is generally recommended to treat high-grade "grade 3" breast carcinoma with chemotherapy because they are chemosensitive and will often recur otherwise. By contrast, most low-grade "grade 1" tumors should not be treated with chemotherapy because they have a good prognosis and are often chemo-insensitive.